SCHEMBL160333

SCHEMBL160333

COc1ccc(NC(=O)Nc2ccc(-c3cnc(CC(C)(C)C(=O)O)s3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.47
RAB9A P51151 7/20 0.47
NPC1 O15118 6/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
CSNK2A2 P19784 1/20 0.47
CSNK2A1 P68400 1/20 0.47
MAPT P10636 6/20 0.47
HIF1A Q16665 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 4/20 0.45
LMNA P02545 3/20 0.45
POLB P06746 2/20 0.44
SAE1 Q9UBE0 1/20 0.44
UBA2 Q9UBT2 1/20 0.44
TSHR P16473 2/20 0.44
GLA P06280 1/20 0.44
TP53 P04637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164317 0.92 CNR1 (0.47) CNR1RAB9ANPC1SMN1; SMN2CSNK2A2
SCHEMBL162024 0.90 MAPT (0.46) CNR1RAB9ANPC1SMN1; SMN2CSNK2A2
SCHEMBL158262 0.87 DGAT1 (0.45) CNR1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL164989 0.85 DGAT1 (0.48) CNR1RAB9ANPC1MEN1KMT2A
SCHEMBL161205 0.83 MAPT (0.46) CNR1RAB9ANPC1SMN1; SMN2CSNK2A2
SCHEMBL159978 0.82 DGAT1 (0.58) CNR1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL164945 0.81 MAPT (0.44) CNR1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL163195 0.81 EPHX1 (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL162274 0.79 DGAT1 (0.45) NPC1MAPTMEN1KMT2ALMNA
SCHEMBL165688 0.79 DGAT1 (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 CNR1 946/4885RAB9A 1781/4885NPC1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.